Sandoz’s Bourdage Makes Case For Tailored Biosimilar Pathways

Current Approach Of Phase III Studies ‘Is No Longer Justified In Many Cases’

 
• By David Wallace
  
Generate a summary of this article
Listen to this article
Beta

A strong case exists for a more tailored approach to biosimilars development that could increase regulatory efficiency and broaden access, Sandoz’s head of biopharmaceuticals, Pierre Bourdage, tells Generics Bulletin in an exclusive interview.

Pierre Bourdage, Sandoz head of biopharmaceuticals
Sandoz’s Pierre Bourdage sets out the case for tailored biosimilar development • Source: Sandoz

With 2021 marking 15 years since the first biosimilar, Sandoz’s Omintrope (somatropin), was approved and launched in the EU, the company’s head of biopharmaceuticals, Pierre Bourdage, has reflected on the global progress made so far on biosimilars – as well as the opportunities that exist for future evolution – in an exclusive two-part interview with Generics Bulletin.

“Since Sandoz started its first biosimilar development program in 1996, we have seen many advancements in science and technology, also...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.